An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) - GBM AGILE: Glioblastoma Adaptive Global Innovative Learning Environment

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2022
This article has no abstract
Epistemonikos ID: 0dae5cdee755c996524c01fc394f641983c1f3d1
First added on: Apr 17, 2025